Article By:
Scott Matusow
Monday, August 2, 2021 8:59 PM EDT
Calithera is guiding for the market to expect what we believe will be a key data read-out in Q3 from its ongoing CB-280 study involving Cystic Fibrosis. A positive read-out here could see a significant upside for the company stock.
Calithera Biosciences: An Under The Radar Opportunity
$CALA sounds like a good buy.